Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Relinde I Y LieverseEvert J Van LimbergenCary J G OberijeEsther G C TroostSine R HadrupAnne-Marie C DingemansLizza E L HendriksFranziska EckertCrispin HileyChristophe DoomsYolande LievensMonique C de JongJohan BussinkXavier GeetsVincenzo ValentiniGiuliano EliaDario NeriCharlotte BillietAmir AbdollahiDavid PasquierPierre BoisselierAla YarominaDirk De RuysscherLudwig J DuboisPhilippe LambinPublished in: BMC cancer (2020)
ImmunoSABR Protocol Code: NL67629.068.18; EudraCT: 2018-002583-11; Clinicaltrials.gov: NCT03705403; ISRCTN ID: ISRCTN49817477; Date of registration: 03-April-2019.
Keyphrases
- open label
- study protocol
- end stage renal disease
- clinical trial
- ejection fraction
- healthcare
- small cell lung cancer
- newly diagnosed
- randomized controlled trial
- early stage
- chronic kidney disease
- palliative care
- prognostic factors
- brain metastases
- radiation therapy
- squamous cell carcinoma
- phase ii
- pain management
- phase iii